People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Akari Therapeutics Plc | — | Biotechnology | Series C | $140.5M | $34.0M | 2015 |
| Evecxia, Inc. | — | Biotechnology | Series A | $23.1M | $13.5M | 2025 |
Allan Shaw at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Allan Shaw on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Hoyoung Huh | 1 | 7 |
| David Sidransky | 1 | 7 |
| Samir Patel | 1 | 7 |
| JAMES HILL | 1 | 6 |
| MARK COHEN | 1 | 5 |
| Yuval Cohen | 1 | 4 |
| Wendy DiCicco | 1 | 4 |
| Donald Williams | 1 | 4 |
| DOV ELEFANT | 1 | 3 |
| Roger Jeffs | 1 | 3 |
| Johnson Lau | 1 | 3 |
| Michael Grissinger | 1 | 2 |
| Torsten Hombeck | 1 | 2 |
| GILEAD RADAY | 1 | 2 |
| Thomas Aasen | 1 | 2 |
| Wa'el Hashad | 1 | 2 |
| Robert Doman | 1 | 2 |
| John Kaiser | 1 | 2 |
| Fredric Price | 1 | 2 |
| Gur Roshwalb | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.